I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Diabetic
Retinopathy Treatment by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Diabetic Retinopathy
Treatment by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Diabetic Retinopathy
Treatment by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa Markets for Years 2012,
2020 & 2027

Table 4: World Current & Future Analysis for Proliferative
Diabetic Retinopathy by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027 and % CAGR

Table 5: World Historic Review for Proliferative Diabetic
Retinopathy by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for Proliferative Diabetic
Retinopathy by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2012, 2020 & 2027

Table 7: World Current & Future Analysis for Non-Proliferative
Diabetic Retinopathy by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027 and % CAGR

Table 8: World Historic Review for Non-Proliferative Diabetic
Retinopathy by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 9: World 15-Year Perspective for Non-Proliferative
Diabetic Retinopathy by Geographic Region - Percentage
Breakdown of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2012, 2020 & 2027

Table 10: World Current & Future Analysis for Anti-VEGF by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 11: World Historic Review for Anti-VEGF by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 12: World 15-Year Perspective for Anti-VEGF by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Intraocular
Steroid Injection by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027 and % CAGR

Table 14: World Historic Review for Intraocular Steroid
Injection by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 15: World 15-Year Perspective for Intraocular Steroid
Injection by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027

Table 16: World Current & Future Analysis for Laser Surgery by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 17: World Historic Review for Laser Surgery by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 18: World 15-Year Perspective for Laser Surgery by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Vitrectomy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 20: World Historic Review for Vitrectomy by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 21: World 15-Year Perspective for Vitrectomy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 22: USA Current & Future Analysis for Diabetic
Retinopathy Treatment by Type - Proliferative Diabetic
Retinopathy and Non-Proliferative Diabetic Retinopathy -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 23: USA Historic Review for Diabetic Retinopathy
Treatment by Type - Proliferative Diabetic Retinopathy and
Non-Proliferative Diabetic Retinopathy Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 24: USA 15-Year Perspective for Diabetic Retinopathy
Treatment by Type - Percentage Breakdown of Value Sales for
Proliferative Diabetic Retinopathy and Non-Proliferative
Diabetic Retinopathy for the Years 2012, 2020 & 2027

Table 25: USA Current & Future Analysis for Diabetic
Retinopathy Treatment by Management - Anti-VEGF, Intraocular
Steroid Injection, Laser Surgery and Vitrectomy - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 26: USA Historic Review for Diabetic Retinopathy
Treatment by Management - Anti-VEGF, Intraocular Steroid
Injection, Laser Surgery and Vitrectomy Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 27: USA 15-Year Perspective for Diabetic Retinopathy
Treatment by Management - Percentage Breakdown of Value Sales
for Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and
Vitrectomy for the Years 2012, 2020 & 2027

CANADA
Table 28: Canada Current & Future Analysis for Diabetic
Retinopathy Treatment by Type - Proliferative Diabetic
Retinopathy and Non-Proliferative Diabetic Retinopathy -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 29: Canada Historic Review for Diabetic Retinopathy
Treatment by Type - Proliferative Diabetic Retinopathy and
Non-Proliferative Diabetic Retinopathy Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 30: Canada 15-Year Perspective for Diabetic Retinopathy
Treatment by Type - Percentage Breakdown of Value Sales for
Proliferative Diabetic Retinopathy and Non-Proliferative
Diabetic Retinopathy for the Years 2012, 2020 & 2027

Table 31: Canada Current & Future Analysis for Diabetic
Retinopathy Treatment by Management - Anti-VEGF, Intraocular
Steroid Injection, Laser Surgery and Vitrectomy - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 32: Canada Historic Review for Diabetic Retinopathy
Treatment by Management - Anti-VEGF, Intraocular Steroid
Injection, Laser Surgery and Vitrectomy Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 33: Canada 15-Year Perspective for Diabetic Retinopathy
Treatment by Management - Percentage Breakdown of Value Sales
for Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and
Vitrectomy for the Years 2012, 2020 & 2027

JAPAN
Table 34: Japan Current & Future Analysis for Diabetic
Retinopathy Treatment by Type - Proliferative Diabetic
Retinopathy and Non-Proliferative Diabetic Retinopathy -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 35: Japan Historic Review for Diabetic Retinopathy
Treatment by Type - Proliferative Diabetic Retinopathy and
Non-Proliferative Diabetic Retinopathy Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 36: Japan 15-Year Perspective for Diabetic Retinopathy
Treatment by Type - Percentage Breakdown of Value Sales for
Proliferative Diabetic Retinopathy and Non-Proliferative
Diabetic Retinopathy for the Years 2012, 2020 & 2027

Table 37: Japan Current & Future Analysis for Diabetic
Retinopathy Treatment by Management - Anti-VEGF, Intraocular
Steroid Injection, Laser Surgery and Vitrectomy - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 38: Japan Historic Review for Diabetic Retinopathy
Treatment by Management - Anti-VEGF, Intraocular Steroid
Injection, Laser Surgery and Vitrectomy Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 39: Japan 15-Year Perspective for Diabetic Retinopathy
Treatment by Management - Percentage Breakdown of Value Sales
for Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and
Vitrectomy for the Years 2012, 2020 & 2027

CHINA
Table 40: China Current & Future Analysis for Diabetic
Retinopathy Treatment by Type - Proliferative Diabetic
Retinopathy and Non-Proliferative Diabetic Retinopathy -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 41: China Historic Review for Diabetic Retinopathy
Treatment by Type - Proliferative Diabetic Retinopathy and
Non-Proliferative Diabetic Retinopathy Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 42: China 15-Year Perspective for Diabetic Retinopathy
Treatment by Type - Percentage Breakdown of Value Sales for
Proliferative Diabetic Retinopathy and Non-Proliferative
Diabetic Retinopathy for the Years 2012, 2020 & 2027

Table 43: China Current & Future Analysis for Diabetic
Retinopathy Treatment by Management - Anti-VEGF, Intraocular
Steroid Injection, Laser Surgery and Vitrectomy - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 44: China Historic Review for Diabetic Retinopathy
Treatment by Management - Anti-VEGF, Intraocular Steroid
Injection, Laser Surgery and Vitrectomy Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 45: China 15-Year Perspective for Diabetic Retinopathy
Treatment by Management - Percentage Breakdown of Value Sales
for Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and
Vitrectomy for the Years 2012, 2020 & 2027

EUROPE
Table 46: Europe Current & Future Analysis for Diabetic
Retinopathy Treatment by Geographic Region - France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 47: Europe Historic Review for Diabetic Retinopathy
Treatment by Geographic Region - France, Germany, Italy, UK,
Spain, Russia and Rest of Europe Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 48: Europe 15-Year Perspective for Diabetic Retinopathy
Treatment by Geographic Region - Percentage Breakdown of Value
Sales for France, Germany, Italy, UK, Spain, Russia and Rest of
Europe Markets for Years 2012, 2020 & 2027

Table 49: Europe Current & Future Analysis for Diabetic
Retinopathy Treatment by Type - Proliferative Diabetic
Retinopathy and Non-Proliferative Diabetic Retinopathy -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 50: Europe Historic Review for Diabetic Retinopathy
Treatment by Type - Proliferative Diabetic Retinopathy and
Non-Proliferative Diabetic Retinopathy Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 51: Europe 15-Year Perspective for Diabetic Retinopathy
Treatment by Type - Percentage Breakdown of Value Sales for
Proliferative Diabetic Retinopathy and Non-Proliferative
Diabetic Retinopathy for the Years 2012, 2020 & 2027

Table 52: Europe Current & Future Analysis for Diabetic
Retinopathy Treatment by Management - Anti-VEGF, Intraocular
Steroid Injection, Laser Surgery and Vitrectomy - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 53: Europe Historic Review for Diabetic Retinopathy
Treatment by Management - Anti-VEGF, Intraocular Steroid
Injection, Laser Surgery and Vitrectomy Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 54: Europe 15-Year Perspective for Diabetic Retinopathy
Treatment by Management - Percentage Breakdown of Value Sales
for Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and
Vitrectomy for the Years 2012, 2020 & 2027

FRANCE
Table 55: France Current & Future Analysis for Diabetic
Retinopathy Treatment by Type - Proliferative Diabetic
Retinopathy and Non-Proliferative Diabetic Retinopathy -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 56: France Historic Review for Diabetic Retinopathy
Treatment by Type - Proliferative Diabetic Retinopathy and
Non-Proliferative Diabetic Retinopathy Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 57: France 15-Year Perspective for Diabetic Retinopathy
Treatment by Type - Percentage Breakdown of Value Sales for
Proliferative Diabetic Retinopathy and Non-Proliferative
Diabetic Retinopathy for the Years 2012, 2020 & 2027

Table 58: France Current & Future Analysis for Diabetic
Retinopathy Treatment by Management - Anti-VEGF, Intraocular
Steroid Injection, Laser Surgery and Vitrectomy - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 59: France Historic Review for Diabetic Retinopathy
Treatment by Management - Anti-VEGF, Intraocular Steroid
Injection, Laser Surgery and Vitrectomy Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 60: France 15-Year Perspective for Diabetic Retinopathy
Treatment by Management - Percentage Breakdown of Value Sales
for Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and
Vitrectomy for the Years 2012, 2020 & 2027

GERMANY
Table 61: Germany Current & Future Analysis for Diabetic
Retinopathy Treatment by Type - Proliferative Diabetic
Retinopathy and Non-Proliferative Diabetic Retinopathy -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 62: Germany Historic Review for Diabetic Retinopathy
Treatment by Type - Proliferative Diabetic Retinopathy and
Non-Proliferative Diabetic Retinopathy Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 63: Germany 15-Year Perspective for Diabetic Retinopathy
Treatment by Type - Percentage Breakdown of Value Sales for
Proliferative Diabetic Retinopathy and Non-Proliferative
Diabetic Retinopathy for the Years 2012, 2020 & 2027

Table 64: Germany Current & Future Analysis for Diabetic
Retinopathy Treatment by Management - Anti-VEGF, Intraocular
Steroid Injection, Laser Surgery and Vitrectomy - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 65: Germany Historic Review for Diabetic Retinopathy
Treatment by Management - Anti-VEGF, Intraocular Steroid
Injection, Laser Surgery and Vitrectomy Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 66: Germany 15-Year Perspective for Diabetic Retinopathy
Treatment by Management - Percentage Breakdown of Value Sales
for Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and
Vitrectomy for the Years 2012, 2020 & 2027

ITALY
Table 67: Italy Current & Future Analysis for Diabetic
Retinopathy Treatment by Type - Proliferative Diabetic
Retinopathy and Non-Proliferative Diabetic Retinopathy -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 68: Italy Historic Review for Diabetic Retinopathy
Treatment by Type - Proliferative Diabetic Retinopathy and
Non-Proliferative Diabetic Retinopathy Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 69: Italy 15-Year Perspective for Diabetic Retinopathy
Treatment by Type - Percentage Breakdown of Value Sales for
Proliferative Diabetic Retinopathy and Non-Proliferative
Diabetic Retinopathy for the Years 2012, 2020 & 2027

Table 70: Italy Current & Future Analysis for Diabetic
Retinopathy Treatment by Management - Anti-VEGF, Intraocular
Steroid Injection, Laser Surgery and Vitrectomy - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 71: Italy Historic Review for Diabetic Retinopathy
Treatment by Management - Anti-VEGF, Intraocular Steroid
Injection, Laser Surgery and Vitrectomy Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 72: Italy 15-Year Perspective for Diabetic Retinopathy
Treatment by Management - Percentage Breakdown of Value Sales
for Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and
Vitrectomy for the Years 2012, 2020 & 2027

UNITED KINGDOM
Table 73: UK Current & Future Analysis for Diabetic Retinopathy
Treatment by Type - Proliferative Diabetic Retinopathy and
Non-Proliferative Diabetic Retinopathy - Independent Analysis
of Annual Sales in US$ Million for the Years 2020 through 2027
and % CAGR

Table 74: UK Historic Review for Diabetic Retinopathy Treatment
by Type - Proliferative Diabetic Retinopathy and
Non-Proliferative Diabetic Retinopathy Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 75: UK 15-Year Perspective for Diabetic Retinopathy
Treatment by Type - Percentage Breakdown of Value Sales for
Proliferative Diabetic Retinopathy and Non-Proliferative
Diabetic Retinopathy for the Years 2012, 2020 & 2027

Table 76: UK Current & Future Analysis for Diabetic Retinopathy
Treatment by Management - Anti-VEGF, Intraocular Steroid
Injection, Laser Surgery and Vitrectomy - Independent Analysis
of Annual Sales in US$ Million for the Years 2020 through 2027
and % CAGR

Table 77: UK Historic Review for Diabetic Retinopathy Treatment
by Management - Anti-VEGF, Intraocular Steroid Injection, Laser
Surgery and Vitrectomy Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 78: UK 15-Year Perspective for Diabetic Retinopathy
Treatment by Management - Percentage Breakdown of Value Sales
for Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and
Vitrectomy for the Years 2012, 2020 & 2027

SPAIN
Table 79: Spain Current & Future Analysis for Diabetic
Retinopathy Treatment by Type - Proliferative Diabetic
Retinopathy and Non-Proliferative Diabetic Retinopathy -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 80: Spain Historic Review for Diabetic Retinopathy
Treatment by Type - Proliferative Diabetic Retinopathy and
Non-Proliferative Diabetic Retinopathy Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 81: Spain 15-Year Perspective for Diabetic Retinopathy
Treatment by Type - Percentage Breakdown of Value Sales for
Proliferative Diabetic Retinopathy and Non-Proliferative
Diabetic Retinopathy for the Years 2012, 2020 & 2027

Table 82: Spain Current & Future Analysis for Diabetic
Retinopathy Treatment by Management - Anti-VEGF, Intraocular
Steroid Injection, Laser Surgery and Vitrectomy - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 83: Spain Historic Review for Diabetic Retinopathy
Treatment by Management - Anti-VEGF, Intraocular Steroid
Injection, Laser Surgery and Vitrectomy Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 84: Spain 15-Year Perspective for Diabetic Retinopathy
Treatment by Management - Percentage Breakdown of Value Sales
for Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and
Vitrectomy for the Years 2012, 2020 & 2027

RUSSIA
Table 85: Russia Current & Future Analysis for Diabetic
Retinopathy Treatment by Type - Proliferative Diabetic
Retinopathy and Non-Proliferative Diabetic Retinopathy -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 86: Russia Historic Review for Diabetic Retinopathy
Treatment by Type - Proliferative Diabetic Retinopathy and
Non-Proliferative Diabetic Retinopathy Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 87: Russia 15-Year Perspective for Diabetic Retinopathy
Treatment by Type - Percentage Breakdown of Value Sales for
Proliferative Diabetic Retinopathy and Non-Proliferative
Diabetic Retinopathy for the Years 2012, 2020 & 2027

Table 88: Russia Current & Future Analysis for Diabetic
Retinopathy Treatment by Management - Anti-VEGF, Intraocular
Steroid Injection, Laser Surgery and Vitrectomy - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 89: Russia Historic Review for Diabetic Retinopathy
Treatment by Management - Anti-VEGF, Intraocular Steroid
Injection, Laser Surgery and Vitrectomy Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 90: Russia 15-Year Perspective for Diabetic Retinopathy
Treatment by Management - Percentage Breakdown of Value Sales
for Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and
Vitrectomy for the Years 2012, 2020 & 2027

REST OF EUROPE
Table 91: Rest of Europe Current & Future Analysis for Diabetic
Retinopathy Treatment by Type - Proliferative Diabetic
Retinopathy and Non-Proliferative Diabetic Retinopathy -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 92: Rest of Europe Historic Review for Diabetic
Retinopathy Treatment by Type - Proliferative Diabetic
Retinopathy and Non-Proliferative Diabetic Retinopathy Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 93: Rest of Europe 15-Year Perspective for Diabetic
Retinopathy Treatment by Type - Percentage Breakdown of Value
Sales for Proliferative Diabetic Retinopathy and
Non-Proliferative Diabetic Retinopathy for the Years 2012, 2020 &
2027

Table 94: Rest of Europe Current & Future Analysis for Diabetic
Retinopathy Treatment by Management - Anti-VEGF, Intraocular
Steroid Injection, Laser Surgery and Vitrectomy - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 95: Rest of Europe Historic Review for Diabetic
Retinopathy Treatment by Management - Anti-VEGF, Intraocular
Steroid Injection, Laser Surgery and Vitrectomy Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 96: Rest of Europe 15-Year Perspective for Diabetic
Retinopathy Treatment by Management - Percentage Breakdown of
Value Sales for Anti-VEGF, Intraocular Steroid Injection, Laser
Surgery and Vitrectomy for the Years 2012, 2020 & 2027

ASIA-PACIFIC
Table 97: Asia-Pacific Current & Future Analysis for Diabetic
Retinopathy Treatment by Geographic Region - Australia, India,
South Korea and Rest of Asia-Pacific Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 98: Asia-Pacific Historic Review for Diabetic Retinopathy
Treatment by Geographic Region - Australia, India, South Korea
and Rest of Asia-Pacific Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 99: Asia-Pacific 15-Year Perspective for Diabetic
Retinopathy Treatment by Geographic Region - Percentage
Breakdown of Value Sales for Australia, India, South Korea and
Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027

Table 100: Asia-Pacific Current & Future Analysis for Diabetic
Retinopathy Treatment by Type - Proliferative Diabetic
Retinopathy and Non-Proliferative Diabetic Retinopathy -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 101: Asia-Pacific Historic Review for Diabetic
Retinopathy Treatment by Type - Proliferative Diabetic
Retinopathy and Non-Proliferative Diabetic Retinopathy Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 102: Asia-Pacific 15-Year Perspective for Diabetic
Retinopathy Treatment by Type - Percentage Breakdown of Value
Sales for Proliferative Diabetic Retinopathy and
Non-Proliferative Diabetic Retinopathy for the Years 2012, 2020 &
2027

Table 103: Asia-Pacific Current & Future Analysis for Diabetic
Retinopathy Treatment by Management - Anti-VEGF, Intraocular
Steroid Injection, Laser Surgery and Vitrectomy - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 104: Asia-Pacific Historic Review for Diabetic
Retinopathy Treatment by Management - Anti-VEGF, Intraocular
Steroid Injection, Laser Surgery and Vitrectomy Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 105: Asia-Pacific 15-Year Perspective for Diabetic
Retinopathy Treatment by Management - Percentage Breakdown of
Value Sales for Anti-VEGF, Intraocular Steroid Injection, Laser
Surgery and Vitrectomy for the Years 2012, 2020 & 2027

AUSTRALIA
Table 106: Australia Current & Future Analysis for Diabetic
Retinopathy Treatment by Type - Proliferative Diabetic
Retinopathy and Non-Proliferative Diabetic Retinopathy -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 107: Australia Historic Review for Diabetic Retinopathy
Treatment by Type - Proliferative Diabetic Retinopathy and
Non-Proliferative Diabetic Retinopathy Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 108: Australia 15-Year Perspective for Diabetic
Retinopathy Treatment by Type - Percentage Breakdown of Value
Sales for Proliferative Diabetic Retinopathy and
Non-Proliferative Diabetic Retinopathy for the Years 2012, 2020 &
2027

Table 109: Australia Current & Future Analysis for Diabetic
Retinopathy Treatment by Management - Anti-VEGF, Intraocular
Steroid Injection, Laser Surgery and Vitrectomy - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 110: Australia Historic Review for Diabetic Retinopathy
Treatment by Management - Anti-VEGF, Intraocular Steroid
Injection, Laser Surgery and Vitrectomy Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 111: Australia 15-Year Perspective for Diabetic
Retinopathy Treatment by Management - Percentage Breakdown of
Value Sales for Anti-VEGF, Intraocular Steroid Injection, Laser
Surgery and Vitrectomy for the Years 2012, 2020 & 2027

INDIA
Table 112: India Current & Future Analysis for Diabetic
Retinopathy Treatment by Type - Proliferative Diabetic
Retinopathy and Non-Proliferative Diabetic Retinopathy -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and